Research

Hormonal

Dual GLP1R/GIPR agonists achieve superior glucose lowering and weight reduction compared to single GLP1R agonists through specific engagement of pancreatic islet cells (beta, alpha, delta) and circumventricular organ neurons, rather than through enhanced brain penetration.

Dual GLP1/GIP agonists work better than single GLP1 drugs because they target specific cells in the pancreas (beta, alpha, delta) and specific neurons in the brain's edge (circumventricular organs), not because they penetrate the brain deeper. This targeted engagement drives superior glucose and weight outcomes.

GoodSupportsHIGH confidence
Compared to GLP1R agonists, dual agonists show superior efficacy for glucose lowering and weight reduction... daLUXendins reveal dual agonist targets in the pancreas and brain and exclude a role for brain penetration in determining the superior efficacy of dual agonists
Anne de Bray et al. · Nature Metabolism · 2025

Why this rating

High-quality preclinical data using novel fluorescent probes in rodent and human stem-cell models, though human clinical pharmacokinetics are not fully detailed.

Source

Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain

Anne de Bray et al. · Nature Metabolism · 2025

DOI 10.1038/s42255-025-01342-6

mechanism_onlyCited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →